Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent (NYSE:A) expanded its Altura HPLC column portfolio with new Altura size exclusion (SEC) and Altura PLRP-S columns for biotherapeutic analysis.
The columns use Ultra Inert technology to improve peak shape, sensitivity, aggregate recovery and conditioning across peptides, proteins, oligonucleotides, antibody-drug conjugates and other complex modalities, and are available globally.
Agilent (NYSE:A) launched xCELLigence RTCA eSight AI, an AI-powered software module for its RTCA eSight instrument. The module automates label-free imaging analysis, reducing manual cell segmentation and parameter tuning while supporting standardized, dual imaging and impedance readouts from the same cells.
It targets drug discovery and high-throughput biopharma research and builds on Agilent’s 2025 revenue base of $6.95 billion and approximately 18,000 employees worldwide.
Agilent (NYSE:A) completed its acquisition of Biocare Medical, a global clinical pathology provider, from an investor group led by Excellere Partners and GHO Capital Partners. Biocare joins Agilent’s Life Sciences and Diagnostics Markets Group.
According to Agilent, the deal is expected to be accretive to top-line growth, margin profile and non-instrument revenue mix in year one, and to EPS about 12 months after close. The company plans to outline the expected FY2026 financial impact in its third-quarter earnings release.
Agilent Technologies (NYSE:A) announced a collaboration with OpenAI and Boston Consulting Group (BCG) to deploy artificial intelligence across its products, operations, and customer workflows.
Initial AI use cases focus on enhancing customer experience and speeding the new product pipeline, with plans to expand efforts over the next 6–12 months.
Agilent (NYSE:A) received U.S. FDA approval to expand use of PD-L1 IHC 22C3 pharmDx (Code GE006) on the Dako Omnis platform. The test can now help identify esophageal squamous cell carcinoma, triple‑negative breast cancer, cervical cancer, and gastric or GEJ adenocarcinoma patients who may be eligible for treatment with KEYTRUDA.
This extends prior approvals in NSCLC and HNSCC and adds Dako Omnis alongside Autostainer Link 48. A multisite study met acceptance criteria for inter‑platform concordance, supporting consolidated, automated PD-L1 testing workflows.
Agilent (NYSE:A) announced OpenLab Sync, a Lab Execution System that digitally connects workflows from method design to bench execution. The system delivers guided, standardized, traceable procedures for regulated labs, integrates USP MethodConnect for machine-readable USP–NF content, and uses AI to streamline setup, integration, and monitoring.
Designed for pharmaceutical quality control and other regulated environments, OpenLab Sync supports data integrity, audit readiness, and scalable global workflows within the OpenLab ecosystem. According to Agilent, the company generated $6.95 billion revenue in fiscal 2025 and employs about 18,000 people worldwide.
Agilent (NYSE:A) reported second-quarter fiscal 2026 revenue of $1.83 billion, up 10.0% reported and 6.3% core year-over-year. GAAP EPS was $1.20 and non-GAAP EPS $1.49, rising 60% and 14% respectively.
The company raised fiscal 2026 guidance, now expecting revenue of $7.39–$7.49 billion and non-GAAP EPS of $6.00–$6.10. Q2 non-GAAP operating margin reached 26.4%, with all three business groups delivering reported revenue growth of 6–14%.
Agilent (NYSE:A) launched a new multi-attribute method (MAM) LC/HRMS workflow for pharmaceutical and biopharmaceutical quality control laboratories. The solution combines software, instruments, columns, consumables, and standards to support routine, regulated testing and monitoring of critical quality attributes in late-stage development and commercial manufacturing.
The workflow integrates with OpenLab CDS to support method transfer from R&D into manufacturing and is available globally. Agilent reports fiscal 2025 revenue of $6.95 billion and a workforce of about 18,000 worldwide.
Agilent (NYSE:A) launched its 8890B GC and 8860B GC systems featuring GC Assist, an integrated intelligence platform for system monitoring, diagnostics, and remote connectivity. The instruments aim to reduce downtime, improve data quality, and boost laboratory efficiency and throughput through faster oven cooling, added detector capacity, and guided maintenance.
GC Assist supports continuous performance monitoring, quality control alerts, and maintenance guidance. The systems are introduced globally and backed by Agilent’s worldwide sales, service, and application teams. Agilent reported $6.95 billion in fiscal 2025 revenue and employs about 18,000 people.
Agilent (NYSE:A) launched the 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system aimed at labs moving from single to triple quadrupole technology.
The 9500 offers over 33% typical reduction in acquisition time, advanced interference removal via Air Cell and Advanced Helium Mode using the Dual-Cell System, and integration with OpenLab ICP-MS software. It targets environmental, food, pharma, chemical, materials, and contract testing labs, aiming to boost productivity, reduce reruns, and lessen reliance on oxygen cylinders.